| Proposal number |
Study Sponsor(s) |
Title |
Institution |
Lead researcher |
|
| 611 | GSK | Long-acting beta2-agonists for chronic obstructive pulmonary disease | Cochrane Airways Group, at St George's University of London | Kayleigh Kew | Further Details |
| 628 | GSK | Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib | Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada | Arnoud J. Templeton, MD | Further Details |
| 631 | GSK | Predictors of BPH Progression | Duke University | Dr. Stephen Freedland, MD | Further Details |
| 637 | GSK | Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial | New York University school of Medicine, NY, NY | Sripal Bangalore | Further Details |
| 639 | GSK | Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease | St Luke's-Roosevelt Hospital of the Columbia University of Physicians and Surgeons | Saurav Chatterjee MD | Further Details |
| 645 | GSK | The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension | New York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NY | Partha Sardar | Further Details |
| 646 | GSK | Factors influencing immune response and patient outcomes following influenza vaccination. | Health Protection Research Group, University of Nottingham | Dr Subhadra Rajanaidu | Further Details |
| 647 | GSK | Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials | Institute for Clinical Research and Health Policy Studies, Tufts Medical Center | David M. Kent, MD, MSc | Further Details |
| 651 | GSK | Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children. | P95 Pharmacovigilance and Epidemiology Services | Thomas Verstraeten | Further Details |
| 653 | GSK | Functional Estimation of Interventional Effects | Department of Economics, Indiana University, Bloomington, Professor
Sungkyunkwan University, Professor of Economics | Joon Park | Further Details |
| 654 | GSK, ViiV | Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7) | Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany | Ulrich Jaehde | Further Details |
| 657 | GSK | Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials | McMaster University | Holger Schunemann, MD, MSc, PhD | Further Details |
| 668 | GSK | Associations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertension | Flinders University, School of Medicine, Adelaide, Australia; Southern Adelaide Health Network, Adelaide, Australia | Arduino A Mangoni | Further Details |
| 669 | GSK | A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes. | University of Adelaide | Jon Jureidini | Further Details |
| 672 | GSK | The Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with Lapatinib | Memorial Sloan-Kettering Cancer Center | Dr. Mario Lacouture | Further Details |
| 674 | GSK | Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews andnetwork meta-analysis | University of Liverpool | Antony Marson | Further Details |
| 675 | Novartis | Validation study on magnitude of tumorshrinkage as a prognostic marker | Medical School Hannover
Hematologgy, hemostasis, oncology and stemcelltransplantation
Carl-Neuberg-Str. 1
30627 Hannover, Germany | Viktor Grünwald | Further Details |
| 679 | GSK | An Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to Montelukast | University of North Carolina at Chapel Hill
Division of Pulmonary and Critical Care Medicine
130 Mason Farm Rd
Chapel Hill NC 27599-7020 | Wayne H Anderson | Further Details |
| 681 | GSK | A randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patients | Massachusetts General Hospital | Alexa B. Kimball | Further Details |
| 911 | GSK | Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data | Cedars-Sinai Medical Center | Lindsy Forbess, MD, MSc | Further Details |
| 918 | GSK | Outcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary Syndrome | New York Medical College, New York, NY. | Partha Sardar MD | Further Details |
| 928 | GSK | Lung function and airway inflammation response after ozone exposure 0.25ppm | UNC Hospitals | Krista Todoric, MD | Further Details |
| 930 | GSK | MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies | NIHR Exeter Clinical Research Facility
University of Exeter Medical School
Barrack Road
Exeter
EX2 5DW | Professor Andrew Hattersley, M.D. FRS | Further Details |
| 945 | ViiV | THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS | University Hospital Ramón y CAjal | Santiago Moreno | Further Details |
| 946 | GSK, Novartis, Roche | Assessing models for changes in tumour size over time and how they relate to survival times. | Division of Mathematics, University of Dundee, Dundee, UK. | Raluca Eftimie | Further Details |
| 951 | GSK | Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia | The University of Jordan | Mohammad Saleh | Further Details |
| 955 | GSK | A study of subgroup identification and micro aggregation | National Institute of Statistical Sciences
www.niss.org | S. Stanley Young | Further Details |
| 956 | Roche | Bone Quality Project | University of California, San Francisco | Dennis M. Black | Further Details |
| 976 | GSK | 5-alpha reductase inhibitor use and risk of lung cancer | Department of Internal Medicine
University of Manitoba
Department of Medical Oncology and Hematology
Cancercare Manitoba | Marshall Pitz | Further Details |
| 977 | GSK | The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation | University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich | Milo Puhan | Further Details |
| 980 | GSK | Association of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patients | Institute of Epidemiology and Preventive Medicine, National Taiwan University.
Department of Family Medicine, Renai Branch, Taipei City Hospital | Yi-Fan Wu | Further Details |
| 982 | ViiV | Pharmacokinetic modeling of dolutegravir in HIV patients. | National Brain Research Centre,Manesar,Haryana,Gurgaon,India-122050 | V P Subramanyam Rallabandi | Further Details |
| 988 | Roche | PhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical Data | School of Health and Related Research (ScHARR) at the University of Sheffield | Fabrizio Messina | Further Details |
| 989 | GSK | Assessing at the participant level the applicability of clinical trials to a specific patient | Lister Hill National Center for Biomedical Communications, US National Library of Medicine, NIH | Amos Cahan | Further Details |
| 993 | GSK | A Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD. | Yale University School of Medicine | Carlos A. Vaz Fragoso, MD | Further Details |
| 995 | Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCB | Identifying immune modulating patterns across diseases from open clinical trial data | Institute for Computational Health Sciences
UCSF School of Medicine
Mission Hall - 550 16th St, San Francisco, CA 94158
email:Atul.Butte@ucsf.edu
Phone: 415-514-0511 | | Further Details |
| 997 | GSK | Predictors of Prostate Cancer Progression Among Men on Active Surveillance | Duke University | Stephen Freedland, MD | Further Details |
| 998 | GSK | Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus | Rush University Medical Center | Meenakshi Jolly, MD, MSCP | Further Details |
| 999 | Boehringer Ingelheim, GSK | Assessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized Trials | Thomson Reuters | Kristen M Sweet | Further Details |
| 1000 | GSK | Review of fever and febrile convulsion rates in children after trivalent influenza vaccine. | National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead | Dr Jean Li-Kim-Moy, MBBS, FRACP | Further Details |
| 1002 | GSK | Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease | Kansas City University of Medicine & Biosciences | Michael Sarai | Further Details |
| 1013 | GSK | Biopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized Medicine | Princess Margaret Cancer Centre, University Health Network, Surgical Oncology, Urologist. | Girish Kilkarni, MD, PhD | Further Details |
| 1015 | GSK | Pazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric study | Department of Medical Oncology
University Campus Bio-Medico
Via A. Del Portillo 200, 00128
Rome, Italy | Bruno Vincenzi, MD, PhD | Further Details |
| 1016 | GSK | Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique. | London School of Hygiene and Tropical Medicine | Paul Milligan | Further Details |
| 1020 | GSK | Genomic prediction tools developed using phenotypes from disease progression models | University of Chicago | Manish Sharma, MD | Further Details |
| 1022 | Novartis | Prediction of maximal work load (Wmax)in a bicycle test in patients with COPD. | Dept of Respiratory Medicine & Allergology
Lund University Hospital
22185 Lund, Sweden | Göran Eriksson | Further Details |
| 1028 | ViiV | Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. | Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN | José Ramón Blanco | Further Details |
| 1053 | GSK | Validation of the spirometric LMS equations in the Spanish population | Respiratory department, Universitary Hospital of Araba | Dr. Patricia Sobradillo | Further Details |
| 1057 | GSK | Health-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanib | Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University | Chang Wook Jeong | Further Details |
| 1058 | ViiV | Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data me | Centre for Health & Infectious Diseases Research
Rigshospitalet, University of Copenhagen
CHIP, Department of Infectious Diseases and Rheumatology,
Section 2100, Finsencentret
Blegdamsvej 9
DK-2100 Copenhagen Ø
Denmark | Alvaro H Borges | Further Details |
| 1071 | Boehringer Ingelheim, GSK | Optimising the Analysis of vascular Prevention trials (OA-Prevention) | University of Nottingham | Lisa Woodhouse | Further Details |
| 1073 | GSK | End-of-life trajectories in COPD | CIRO+, centre of expertise for chronic organ failure; Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands | Dr. Daisy J.A. Janssen | Further Details |
| 1075 | Roche | Efficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical Trials | Department of Biostatistics & Bioinformatics
Duke University | Xiaofei Wang | Further Details |
| 1078 | Lilly | Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials | University Hospital Geelong, Australia | Seetal Dodd | Further Details |
| 1079 | ViiV | The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals. | Deparment of Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spaon. | Sergio Serrano-Villar, MD PhD | Further Details |
| 1084 | GSK | Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials. | Karolinska Institutet
Department of Medicine
Unit for Clinical Therapy Research, Inflammatory Diseases
(ClinTRID), D1:00, Karolinska University Hospital, Stockholm, Sweden | Ronald van Vollenhoven, MD, PhD | Further Details |
| 1085 | Roche | Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B | The University of Jordan | Mohammad I Saleh, PhD | Further Details |
| 1086 | ViiV | Abacavir HLA-B*57:01 tolerance and genetic variation within the MHC. | Institute for Immunology & Infectious Diseases, Discovery Way, Murdoch, WA 6150 | Elizabeth Phillips, MD | Further Details |
| 1088 | GSK | A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants. | University of North Carolina at Chapel Hill | Joann Gruber | Further Details |
| 1090 | GSK | Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037) | Fred Hutchinson Cancer Research Center;
Department of Biostatistics, University of Washington | M. Elizabeth Halloran | Further Details |
| 1100 | Boehringer Ingelheim | Systolic blood pressure level and risk of intracerebral hemorrhage. | Julius Center for Health Sciences and Primary Care
UMC Utrecht | Jacoba P Greving | Further Details |
| 1103 | GSK | A study on the possible association between antidepressant response to SSRIs and proneness for side effects | Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden | Elias Eriksson, MD, PhD | Further Details |
| 1108 | GSK | Correlation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis. | Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland | Chaigne Benjamin | Further Details |
| 1125 | Lilly | Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. | Department of Psychiatry and Psychotherapy TU-München | Stefan Leucht | Further Details |
| 1128 | GSK | EuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinoma | Leiden University Medical Center (LUMC) | Prof. H.J. Guchelaar | Further Details |
| 1130 | GSK, UCB | Factors that determine placebo response in epilepsy trials | Center for Biostatistics
Department of Population Health Science and Policy
Icahn School of Medicine at Mount Sinai
One Gustave Levy Place, Box 1077
New York, NY 10029 | Emilia Bagiella | Further Details |
| 1132 | GSK | Cytokine patterns in anti-viral disease vaccines: a knowledge driven approach | Division of Systems Medicine Chief
Department of Pediatrics
Stanford University | Atul J. Butte, MD, PhD | Further Details |
| 1134 | GSK | Incidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studies | AO FBF e Oftalmico, Milano Italy | Prof. Savino Bruno, MD | Further Details |
| 1136 | Takeda | Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab? | University of Michigan | Peter Higgins | Further Details |
| 1137 | GSK | Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. | Imperial College London | Roy Anderson, PhD | Further Details |
| 1140 | Boehringer Ingelheim | Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib | MD Anderson Cancer Center | John Heymach, MD, PhD | Further Details |
| 1141 | GSK | Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes | Nuffield Department of Primary Care Health Sciences, University of Oxford | Merryn Voysey | Further Details |
| 1142 | Boehringer Ingelheim, GSK, UCB | A meta-analysis of Parkinson’s disease | Division of Systems Medicine
Department of Pediatrics
Stanford University | Atul Butte | Further Details |
| 1148 | Lilly | Meta-analysis of the risk of relapse in bipolar disorder | FIDMAG Germanes Hospitalàries & King’s College London | Dr. Joaquim Radua | Further Details |
| 1152 | Boehringer Ingelheim | Advanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trial | Yale School of Medicine
Center for Outcomes Research and Evaluation | Nihar Desai, MD, MPH | Further Details |
| 1154 | GSK | Developing New Outcome Measures for SLE by Deconvoluting Available Datasets | Lupus Research Institute | Peter E. Lipsky, MD | Further Details |
| 1157 | GSK | Quality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial) | Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University | Chang Wook Jeong | Further Details |
| 1159 | ViiV | Validation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa Dataset | University of Alabama at Birmingham | Edward P. Acosta, Pharm.D. | Further Details |
| 1160 | Boehringer Ingelheim | Development of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulation | Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602 | Mark H. Ebell MD, MS | Further Details |
| 1161 | Roche | Novel approaches to the prediction of influenza complications | Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602 | Mark H. Ebell | Further Details |
| 1173 | GSK, Lilly | Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis | Interdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the Netherlands | Ymkje Anna de Vries | Further Details |
| 1180 | GSK | Evaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures. | Department of Internal Medicine, University of Genoa, Genoa, Italy. | Edoardo G. Giannini | Further Details |
| 1186 | GSK | Using generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinoma | IDDI inc | Marc Buyse | Further Details |
| 1206 | GSK | Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL) | Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, Germany | Kuhn, Annegret | Further Details |
| 1224 | GSK | INTERACTION BETWEEN MENINGOCOCCAL SEROGROUP B VACCINE (BEXSERO™) AND ROUTINE INFANT VACCINES ON THE RISK OF OCCURRENCE AND RECURRENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION. | Institut National de Santé Publique du Québec(INSPQ)
and
Laval University | Gaston De Serres | Further Details |
| 1234 | Lilly | Predictors of Placebo Response in Pediatric Patients with Generalized Anxiety Disorder | University of Cincinnati | Jeffrey R. Strawn | Further Details |
| 1236 | GSK | COPERNICUS re-analysis | Magdi Yacoub Institute - Heart Science Centre
National Heart & Lung Institute (Myocardial Function Section)
Harefield Hospital
Hill End Road
Harefield, Middlesex, UB9 6JH | John Cleland | Further Details |
| 1250 | Boehringer Ingelheim, Lilly | The relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patients | Department of Psychiatry II, Ulm University | Markus Koesters | Further Details |
| 1256 | GSK | Population mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patients | Head of Department, Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine research Unit (MORU) | Joel Tarning | Further Details |
| 1257 | GSK | An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data | Yale University School of Medicine
Yale-New Haven Hospital Center for Outcomes Research and Evaluation | Joseph S. Ross, MD, MHS | Further Details |
| 1258 | Roche | Advance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation study | University of Texas, Houston, Texas, USA | Syed Hasan Raza Jafri | Further Details |
| 1273 | GSK | Post-hoc analysis of placebo-controlled trials in children and adolescents with depression | University of Gothenburg | Elias Eriksson | Further Details |
| 1277 | Roche | Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. | Imperial College London | Roy Anderson | Further Details |
| 1280 | GSK | Placebo and nocebo effects in migraine Ver 2 | University Hospitals Tuebingen
Dept. of Internal Medicine
Tuebingen, Germany | Paul Enck | Further Details |
| 1292 | Lilly | Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity | University of California, Los Angeles | Alex Sturm | Further Details |
| 1293 | Roche | INCIDENCE OF BRAIN METASTASES IN METASTATIC BREAST CANCER PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: A METAANYLSIS OF FIVE PROSPECTIVE RANDOMIZED PHASE III TRIALS | Medical University of Vienna, Comprehensive Cancer Center Vienna | Rupert Bartsch | Further Details |
| 1295 | Boehringer Ingelheim | A Swapping Method Based on Covariate Classification for Average TreatmentEffect Estimation. | University of Maryland, Baltimore County (UMBC), Department of Mathematics and statistics | Dr. Bimal Sinha | Further Details |
| 1307 | Takeda | The Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease | Seven Oaks General Hospital Renal Program | Dr. Navdeep Tangri | Further Details |
| 1316 | Boehringer Ingelheim | Blinding (Masking) and the Placebo Effect | University of Michigan Medical School | James Brian Byrd, MD, MS, FAHA, FACC | Further Details |
| 1320 | GSK | Utility of a measure of Lupus Low Disease Activity State in SLE | Monash Health | Pei Xuan Ong (Emily) | Further Details |
| 1321 | GSK | Bone Quality Project | University of California, San Francisco | Dennis M. Black | Further Details |
| 1322 | GSK | Comparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level data | None | Giulio Pareto | Further Details |
| 1323 | Lilly | Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques | KKT Technology pte. ltd. | Praveen Deorani | Further Details |
| 1326 | Lilly | Reliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, Revised | SUNY Upstate Medical University | Steven V. Faraone, Ph.D. | Further Details |
| 1331 | Boehringer Ingelheim | Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke | Medical University of South Carolina in Public Health Sciences | Colleen Bauza | Further Details |
| 1335 | GSK, UCB | Investigation into the natural course of epilepsy and the implications on clinical trials | NINDS, National Institutes of Health | Daniel Goldenholz | Further Details |
| 1341 | Boehringer Ingelheim, GSK, Novartis | Vol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial Results | Dana-Farber Cancer Institute
Harvard Medical School | Geoffrey R. Oxnard | Further Details |
| 1343 | GSK | Improving the Assessment of Systemic Lupus Erythematosus Disease Activity | University of Toronto,
University Health Network | Zahi Touma | Further Details |
| 1373 | GSK | An exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorder | University of Kentucky | Jonathan H. Smith, M.D. | Further Details |
| 1374 | GSK | A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy | University of Pittsburgh | Michael M. Wagner | Further Details |
| 1377 | GSK | The association between patient outcomes under two treatments (ABOUT) in cross-over trials | IDDI
30 avenue provinciale
1340 Louvain-la-Neuve
Belgium | Marc Buyse, ScD | Further Details |
| 1387 | GSK | Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children | Nuffield Department of Primary Care Health Sciences, University of Oxford | Merryn Voysey | Further Details |
| 1393 | Roche | Prognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT study | Department of Internal Medicine, Seoul National University Hospital | Sae-Won Han | Further Details |
| 1401 | Sanofi | Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials | McMaster University | Holger Schunemann | Further Details |
| 1403 | ViiV | Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM | Hospital General Universitario Gregorio Marañón | Juan Berenguer | Further Details |
| 1421 | GSK | Cost utility analysis comparing belimumab against rituximab in systemic lupus erythematosus | Wingate University | Chris Gillette | Further Details |
| 1422 | UCB | Developing new outcome measures for SLE by deconvoluting available data sets | LRI | Peter E. Lipsky, MD | Further Details |
| 1428 | Boehringer Ingelheim | Estimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation. | University Medical Center Utrecht, Utrecht, the Netherlands | Frank L.J. Visseren | Further Details |
| 1430 | GSK | Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials. | Department of Medicine, Solna | Ronald van Vollenhoven | Further Details |
| 1433 | Boehringer Ingelheim, Lilly, Roche | Identification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times. | INSERM U1153 METHODS team, Paris, France | Ludovic Trinquart | Further Details |
| 1450 | Boehringer Ingelheim, Novartis | Understanding effectiveness of new drugs in older adults shortly after market entry. | Brigham and Women's Hospital and Harvard Medical School | Shirley V Wang | Further Details |
| 1451 | GSK | Assessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trial | McGill University | Samy Suissa | Further Details |
| 1452 | GSK | A study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countries | University of North Carolina at Chapel Hill | Sylvia Becker-Dreps | Further Details |
| 1455 | Boehringer Ingelheim | Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack | Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands | Jacoba Greving | Further Details |
| 1456 | ViiV | Impact of ongoing side effects on the efficacy of initial antiretroviral therapy | St Vincent's Hospital, Sydney | Andrew Carr | Further Details |
| 1457 | Lilly | Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. | Department of Psychiatry and Psychotherapy TU-München | Stefan Leucht | Further Details |
| 1461 | Lilly | Regression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alpha | Boston University | Allan J. Walkey | Further Details |
| 1470 | Takeda, UCB | The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | Gastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China
Director, IBD Service, Sheba Medical Center, Tel-Aviv University, Israel | Shomron Ben-Horin M.D. | Further Details |
| 1473 | Roche | Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies | (1) Department of Laboratory Medicine, National Taiwan University Hospital
(2) Institute of Epidemiology and Preventive Medicine, National Taiwan University | Keh-Sung Tsai | Further Details |
| 1475 | Boehringer Ingelheim | Predicting safety and efficacy of afatinib treatment of NSCLC | Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia | Assoc/Prof Michael Sorich | Further Details |
| 1481 | GSK | Efficacy and safety of belimumab in childhood-onset lupus | Columbia University Medical Center
630 168th St, Room PH 10-08
New York NY 10032 | Dr Anca Askanase MD, MPH | Further Details |
| 1514 | Roche | Gain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatment | Department of Ophthalmology,
Seoul National University Bundang Hospital | Park, Sang Jun | Further Details |
| 1526 | GSK | Assessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes. | Department of Management
London School of Economics
Houghton Street
London WC2A 2AE | Lawrence D Phillips | Further Details |
| 1528 | GSK | A Swapping Method for Average Treatment Effect Estimation | Statistics, the University of Maryland at Baltimore County (UMBC) | Bimal Sinha | Further Details |
| 1540 | GSK | IMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice. | Brown University | Dr. Issa Dahabreh | Further Details |
| 1541 | Roche | Item calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures. | Wilmer Eye Institute
Johns Hopkins School of Medicine | Judith E. Goldstein | Further Details |
| 1542 | Boehringer Ingelheim | Optimising the Analysis of vascular Prevention trials (OA-Prevention) | University of Nottingham | Philip Bath | Further Details |
| 1558 | GSK, Novartis | Development of historical control using placebo data from pediatric epilepsy studies | UCB Celltech, UK | Anthony Daniels | Further Details |
| 1566 | Lilly | A microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placebo | University of Utah School of Medicine Department of Psychiatry
&
Psychiatric & Behavioral Solutions LLC | Frederick W. Reimherr MD | Further Details |
| 1567 | Boehringer Ingelheim, Takeda | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | University of Exeter Medical Scool
(Honorary Consultant Physician (Diabetes) Royal Devon and Exeter Hospital) | Andrew Hattersley | Further Details |
| 1569 | GSK | Melancholic symptoms in bipolar depression and response to lamotrigine | Department of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, Canada | Dr. Evyn Peters | Further Details |
| 1572 | Boehringer Ingelheim, Eisai, GSK, Lilly | Research to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs) | Department of Breast and Medical Oncology
National Cancer Center Hospital, National Cancer Center, Japan | Kan Yonemori, MD., PhD | Further Details |
| 1575 | GSK, Lilly | Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder | Interdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the Netherlands | Ymkje Anna de Vries | Further Details |
| 1581 | GSK | MASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapy | University of Bath | Professor Chris Jennison | Further Details |
| 1587 | Astellas | Sex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analyses | dept. of general practice, University Medical Center Groningen, University of Groningen, the Netherlands | Marco H. Blanker, MD PhD | Further Details |
| 1593 | GSK | JANUVIA/JANUMET HTA Submission(Germany) | MSD Sharp & Dohme GmbH | Dr. Rainer Woker | Further Details |
| 1595 | Boehringer Ingelheim, GSK, Lilly, Roche | A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials | Cytel Statistical Software and Services Pvt. Ltd | Sharayu Paranjpe | Further Details |
| 1599 | Roche | Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma. | Flinders University | Michael Sorich | Further Details |
| 1600 | Lilly | Item factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimates | University of California, Los Angeles | Alexandra Sturm, Ph.D. | Further Details |
| 1601 | Sanofi | Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trials | Chief of Surgery, JCHO Nihonmatsu Hospital
Research Professor, Fukushima Medical University | Akira Tsuburaya, MD PhD | Further Details |
| 1619 | Boehringer Ingelheim | Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical models | EBSCO Information Services | Brian S. Alper, MD, MSPH, FAAFP | Further Details |
| 1622 | ViiV | A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies | School of Population and Public Health | Steve Kanters | Further Details |
| 1624 | Lilly | A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs). | The Zucker Hillside Hospital | Christoph U Correll | Further Details |
| 1626 | GSK | Factors associated with Prostate Cancer in Prostate Needle Biopsy | University of Illinois at Chicago | Daniel M. Moreira | Further Details |
| 1629 | GSK | Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children | University of Oxford | Merryn Voysey | Further Details |
| 1630 | GSK | A framework for individualized prediction of the rate and severity of asthma exacerbations | Faculty of Pharmaceutical Sciences and Faculty of Medicine, University of British Columbia | Mohsen Sadatsafavi | Further Details |
| 1633 | ViiV | Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study. | Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN | Jose Ramon Blanco | Further Details |
| 1637 | Novartis | 1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World Benchmarks | University at Buffalo, SUNY | Dr. Jeffrey Lackner | Further Details |
| 1640 | GSK | Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial | Lewis Katz School of Medicine, Temple University. | Victor Kim | Further Details |
| 1643 | Astellas, Lilly, Novartis, Roche | Development of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trials | The Institute of Statistical Mathematics, Research Organization of Information and Systems, Tokyo, Japan | Hisashi Noma | Further Details |
| 1646 | Lilly | Effects of tumor burden change (response) on survival in mesothelioma | Mayo Clinic | Aaron Mansfield | Further Details |
| 1654 | GSK, Lilly | Placebo Response in Major Depressive Disorder. | University of California, Los Angeles | Ariana Anderson | Further Details |
| 1660 | Sanofi | Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare | University of North Carolina at Chapel Hill, Department of Epidemiology, Gillings School of Global Public Health | Jennifer L. Lund | Further Details |
| 1668 | Roche | Quantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016) | Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital | Pei Hu | Further Details |
| 1675 | Lilly | Efficacy and tolerability of SNRIs in depression. | Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden | Elias Eriksson | Further Details |
| 1684 | Roche | ANSELMA
Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysis | Gustave Roussy | BENJAMIN BESSE | Further Details |
| 1688 | Novartis | Translational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression. | National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. | Denis Collins | Further Details |
| 1691 | GSK | Longitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76 | Pfizer | Austin Huang | Further Details |
| 1692 | Boehringer Ingelheim, GSK | Predictors of chronic obstructive pulmonary disease progression | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, Japan | Akihiro Hisaka | Further Details |
| 1693 | Lilly, Novartis | Identifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level Data | University of Manchester | Nophar Geifman | Further Details |
| 1695 | GSK | Outcome measures and baseline predictors of response to belimumab treatment. | Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden | Ioannis Parodis | Further Details |
| 1702 | Roche | Pooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patients | Institut Jules Bordet
BrEAST Data Center, Brussels Belgium | Evandro de Azambuja | Further Details |
| 1707 | Lilly | Comparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational Studies | The University of Hong Kong
Duke University (Adjunct) | Herbert Pang | Further Details |
| 1721 | Lilly, Roche | Improving the evaluation of new cancer therapies to expedite patient access | University of Adelaide | Professor Jonathan Karnon | Further Details |
| 1726 | Takeda, UCB | Association Between Obesity and Response to Biologic Therapy in Inflammatory Bowel Diseases | University of California San Diego | Siddharth Singh | Further Details |
| 1731 | GSK | Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data | Department of Epidemiology, Rollins School of Public Health, Emory University | Julia M. Baker | Further Details |
| 1732 | Astellas, Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | University of Glasgow | Dr David A McAllister | Further Details |
| 1733 | Roche | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Rady Faculty of Health Sciences, University of Manitoba
Children's Hospital Research Institute of Manitoba, University of Manitoba | Lily Lim | Further Details |
| 1741 | Lilly, Novartis, Roche | Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer. | Flinders University | Dr Ashley Mark Hopkins | Further Details |
| 1749 | GSK, Novartis, Roche | Bisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-Analyses | Division of Nephrology, Department of Medicine, McMaster University, Department of Health Research Methods, Evidence and Impact, affiliated to Research St. Joseph's - Hamilton | Dr. David Collister | Further Details |
| 1752 | GSK | Sex Differences in responses to umeclidinium-vilanterol treatment in COPD patients | Istituto superiore di sanità, Italy | Elisabetta Straface | Further Details |
| 1758 | Novartis | Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease | Tufts Medical Center/Tufts Medical School | Lesley A. Inker, MD | Further Details |
| 1764 | Sanofi, Takeda | Personalized Medicine Model Builder and Evaluation for Diabetes Treatments | Queens College, CUNY and the Wharton Business School of the University of Pennsylvania | Adam Kapelner | Further Details |
| 1779 | GSK | Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD | Division of Infection, Immunity and Respiratory Medicine
University of Manchester, UK | Professor Jørgen Vestbo DMSc FRCP FERS | Further Details |
| 1786 | Lilly, Novartis, UCB | The efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials data | University of Toronto, Women's College Hospital, Toronto, ON, Canada | Dr Lihi Eder | Further Details |
| 1794 | Roche | A study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials. | Centre for Investigational New Product, National Pharmaceutical Regulatory Agency (NPRA) Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia | OH CHEN WEI | Further Details |
| 1808 | Roche, UCB | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal. | José A. P. da Silva | Further Details |
| 1813 | Takeda | Comparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysis | Mayo Clinic | Purna C. Kashyap, MBBS | Further Details |
| 1816 | Lilly, Roche | Individual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer:
A meta-analysis by the GASTRIC group | Gustave Roussy Cancer Center
Biostatistics and epidemiology dpt
INSERM CESP U1018 OncoStat
Meta-analysis platform
114 rue Ed Vaillant 94805 Villejuif cedex, France | Xavier Paoletti | Further Details |
| 1819 | GSK | INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF ANTIDEPRESSANT TRIALS FOR MAJOR DEPRESSION IN JAPAN | Hiroshima University | Shigeto Yamawaki | Further Details |
| 1831 | GSK, Novartis, Takeda | Statistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized Trials | Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University | Michael Rosenblum | Further Details |
| 1843 | GSK | The genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetes | University of Dundee Dundee DD1 9SY | Ewan Pearson | Further Details |
| 1844 | GSK | Real World Effects of Medications for Chronic Obstructive Pulmonary Disease | London School of Hygiene & Tropical medicine (LSHTM) | Dr Kevin Wing | Further Details |
| 1847 | Sanofi | Antiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy. | University Paris-Sud and Gustave Roussy, Department of Medicine
114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France
Phone: +33 (0)1 42 11 43 22
Fax: +33 (0)1 42 11 52 19 | Benjamin Besse | Further Details |
| 1851 | Roche | Validation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set. | UCSD School of Medicine | Kenneth Kalunian | Further Details |
| 1857 | GSK, Novartis | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis | Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital | Andrea C. Tricco | Further Details |
| 1880 | Boehringer Ingelheim, Eisai, Lilly, Roche, Sanofi | Improving the evaluation of new cancer therapies to expedite patient access | University of Adelaide | Professor Jonathan Karnon | Further Details |
| 1907 | GSK | Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS. | European institute of Oncology , Milan | Tommaso De Pas | Further Details |
| 1911 | Boehringer Ingelheim, Daiichi Sankyo | Lower incidence of atrial fibrillation in NOAC treated patients without prior AF | Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands | Ömer Erküner | Further Details |
| 1925 | GSK | EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysis | University of Liverpool | Catrin Tudur Smith | Further Details |
| 1928 | GSK | The development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1C | The University of Jordan | Mohammad Saleh | Further Details |
| 1933 | Novartis | Benefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harms | University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich | Alessandra Spanu | Further Details |
| 1934 | GSK | Using zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenza | Genentech, Inc., A member of the Roche Group | Lesley Butler | Further Details |
| 1955 | Boehringer Ingelheim | Development and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three months | University Medical Center Utrecht, Utrecht, the Netherlands | F.L.J. Visseren | Further Details |
| 1973 | Roche | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute | Elad Sharon | Further Details |
| 1996 | Sanofi | Statistical Methods for Causal Inference Adjusting for Adherence | Southern Methodist University Department of Statistics
University of Texas Southwestern Medical Center Department of Clinical Sciences | Daniel Heitjan | Further Details |
| 2029 | GSK, Lilly | Matching the Right Antidepressants with the Right Patients: Using Artificial Intelligence to Personalize the Treatment of Depression | Douglas Mental Health University Institute McGill University | Gustavo Turecki | Further Details |
| 2033 | Boehringer Ingelheim | Applying machine learning tools to personalize dabigatran treatment decisions | Stanford University | Sanjay Basu | Further Details |
| 2036 | Boehringer Ingelheim | Prediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED score | Leiden University Medical Centre, Leiden, Netherlands | Menno V Huisman | Further Details |
| 2056 | Lilly | Breakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis. | The Zucker Hillside Hospital,
The Feinstein Institute of Biomedical Research
Northwell Health | Jose M Rubio M.D. | Further Details |
| 2069 | Lilly | Estimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness. | School of Health and Related Research (ScHARR), The University of Sheffield | Ben Kearns | Further Details |
| 2074 | Roche | Association between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial | Institut Jules Bordet | Evandro de Azambuja | Further Details |
| 2084 | GSK | Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation | Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain | Marc Miravitlles | Further Details |
| 2085 | GSK | Identify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial Analysis | Johns Hopkins University
Bloomberg School of Public Health
Department of Health Policy and Management
Center for Drug Safety and Effectiveness
Center for Population Health IT | Hongjun Kan | Further Details |
| 2087 | Lilly | Effectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revised | Founder and Chief Scientific Officer, Ammonett Pharma
Retired from University of Virginia after serving on faculty for 40 years as a clinical investigator, Division Chief Endocrinology and Metabolism, Chairman of the Department of Medicine | Michael O. Thorner | Further Details |
| 2099 | Boehringer Ingelheim | Blood pressure variability in PRoFESS and development of incident stroke | University of Utah, Department of Neurology | Adam de Havenon | Further Details |
| 2100 | GSK | Review of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children. | National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead | Dr Jean Li-Kim-Moy | Further Details |
| 2110 | Lilly | Effects of tumor burden change (response) on survival in mesothelioma | Mayo Clinic | Aaron Mansfield | Further Details |
| 5453 | Roche | Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 5459 | GSK | Placebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving Care | The Ottawa Hospital Research Institute, University of Ottawa | Shawn D. Aaron | Further Details |
| 5460 | GSK | The evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infections | School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong. | Prof Benjamin J Cowling | Further Details |
| 5471 | GSK | Evaluating predictors of antidepressant response or remission in children and adolescents with depression | University of Maryland Baltimore, School of Pharmacy, Pharmaceutical Health Services Research Department | O'Mareen Spence, MPH | Further Details |
| 5494 | Sanofi | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Department of Epidemiology, University of North Carolina at Chapel Hill | Jennifer Lund | Further Details |
| 5495 | Boehringer Ingelheim | Applying clinical trial results in clinical decision-making: Impact of a patien's baseline risk on the relative effect of an intervention strategy. | University Medical Center Utrecht, Utrecht, the Netherlands | Frank L.J. Visseren | Further Details |
| 5499 | Roche | Incorporating biomarkers into survival models to predict patient | Rutgers University | Dr. Luigi Brunetti, PharmD, MPH | Further Details |
| 5501 | Roche | Efficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer; A Combined Analysis | Institut Jules Bordet | Noam Pondé | Further Details |
| 5502 | Lilly | Health Determinants of the quality of life among children with ADHD: a structural equation modelling approach | National Research Council, Neuroscience Institute, Padova, Italy | Nadia Minicuci | Further Details |
| 5504 | Boehringer Ingelheim | Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic Methods | University of North Carolina at Chapel Hill | Michael Webster-Clark | Further Details |
| 5505 | Boehringer Ingelheim, Lilly | A Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive Symptoms | Mayo Clinic, Dept. of Psychiatry and Psychology | William V. Bobo | Further Details |
| 5506 | Lilly | Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed. | Radboud University Medical Center | Rob ter Heine | Further Details |
| 5509 | Boehringer Ingelheim | Statistical methodology for the analysis of incomplete data in non-inferiority clinical trials. | University of Connecticut, Department of Statistics, CT, USA | Yulia Sidi | Further Details |
| 5513 | Lilly, Novartis | Association of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach. | Research Institute Brainclinics, Nijmegen, The Netherlands Utrecht University, Dept. of Experimental Psychology, Utrecht, The Netherlands | Martijn Arns | Further Details |
| 5515 | GSK | Impact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategy | National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 5521 | GSK | Impact of HPV vaccination in preventing subsequent infection and disease after excision treatment | National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 5525 | GSK | Novel approaches for the analysis of SLE clinical trials | Albert Einstein College of Medicine | Mimi Kim | Further Details |
| 5528 | Boehringer Ingelheim | Spirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease | Yale University School of Medicine | Carlos A. Vaz Fragoso, MD | Further Details |
| 5548 | Boehringer Ingelheim, Lilly, Roche | Predictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5549 | Boehringer Ingelheim | Model-based meta-analysis of anticoagulant therapy based on individual patient data | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan | Hisaka Akihiro | Further Details |
| 5565 | Eisai | Predictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5567 | Lilly | PROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome. | University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OH | Tithi Biswas | Further Details |
| 5602 | Roche | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers. | Flinders University | Ashley Hopkins | Further Details |
| 5625 | Roche | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Stanford University | Matthew Baker | Further Details |
| 5642 | GSK | FEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years. | Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada | Don D Sin | Further Details |
| 5644 | GSK, Lilly, Sunovion | Factor analysis using the Generalisability Theory of PANSS data from clinical trials in schizophrenia and bipolar disorder | University Hospital Geelong, Barwon Health, Geelong, Australia | Seetal Dodd | Further Details |
| 5652 | UCB | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | University of California - San Francisco | Vivek Rudrapatna | Further Details |
| 5655 | Astellas, Bayer, Boehringer Ingelheim, GSK, Lilly, Roche, Sanofi, Takeda, ViiV | Prediction of recruitment in randomized clinical trials (RECRUIT-IT) | Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland | Kasenda Benjamin | Further Details |
| 5658 | GSK | Does Shingrix vaccination reduces the risk of stroke? | University of Antwerp & Antwerp University Hospital | Benson Ogunjimi | Further Details |
| 5742 | Boehringer Ingelheim, GSK, Novartis | Comparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTs | Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Head, the Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea | Yeon-Mok Oh | Further Details |
| 5758 | Roche | Predicting the real world effectiveness and safety of medical interventions | Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland | Orestis Efthimiou | Further Details |
| 5769 | GSK | The risk of recurrent Plasmodium vivax malaria and haematological effect of treatment with or without primaquine: a systematic review and individual patient data meta-analysis | Menzies School of Health Research, Darwin, Australia WorldWide Antimalarial Resistance Network (WWARN), University of Oxford, UK | Rob Commons | Further Details |
| 5775 | Roche | Early identification of immunotherapy response based on computational models | Applied Tumor Immunity (D120) National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ) Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany Gastroenterology and Gastrointestinal Oncology University Hospital RWTH Aachen Pauwelsstraße 30, D-52074 Aachen, Germany | Jakob Nikolas Kather | Further Details |
| 5783 | Sanofi | Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy. | VALL D HEBRON INSTITUTE OF ONCOLOGY VALL D'HEBRON UNIVERSITY HOSPITAL Passeig Vall d'Hebron 119-129 08035 BARCELONA | Joan CARLES | Further Details |
| 5791 | Novartis | Trends of CRT therapy in heart failure patients with reduced ejection fraction on LCZ696 versus Enalapril | University of Miami | Abdullah Sarkar MD | Further Details |
| 5793 | Astellas, UCB | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol used in the treatment of rheumatoid arthritis. | Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5796 | GSK | Symptom level analysis of recovery during antidepressant treatment | Department of Psychology and Logopedics, Medical Faculty, University of Helsinki, Helsinki, Finland | Markus Jokela | Further Details |
| 5805 | GSK | Choosing the Right Antidepressant for Depression: Individual Patient Data Network Meta-Analysis | Department of Psychiatry, University of Oxford Oxford Health NHS Foundation Trust | Professor Andrea Cipriani | Further Details |
| 5806 | GSK | Melancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trials | Department of Psychiatry, College of Medicine, University of Saskatchewan | Dr. Evyn Peters | Further Details |
| 5807 | Lilly, Novartis, Roche | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of breast cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5808 | Roche | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Leiden University Medical Center | Diane van der Woude | Further Details |
| 5809 | Roche | Effectiveness of anti HER2 blockade according to host immune status | Gangnam Severance Hospital Department of Surgery | Joon Jeong | Further Details |
| 5814 | UCB | Calculating the Ankylosing Spondylitis Disease Activity Score (ASDAS) in radiographic and non-radiographic axial spondyloarthritis when Patient Global Assessment (PGA) is not available | Leiden University Medical Center (LUMC) | Désirée van der Heijde | Further Details |
| 5815 | GSK | Examining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trials | Imperial College London | Rachel Phillips | Further Details |
| 5819 | GSK | The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data | University of Oxford | Merryn Voysey | Further Details |
| 5835 | GSK | Combined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLE | Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. | Savino Sciascia | Further Details |
| 5836 | Roche | Exploring possibilities to improve the risk:benefit balance through anlaysis of the ocrelizumab phase II extension study | Blizard Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London 4 Newark Street London EC1 2AT | David Baker/Klaus Schmierer | Further Details |
| 5847 | GSK | Effectivity of Belimumab in arthritic and hematologic SLE manifestations | Dep. of Internal Medicine III Carl Gustav Carus Medical Center University of Dresden Germany | Nicolai Leuchten | Further Details |
| 5851 | Novartis | Statistical Methods for Analyzing KCCQ in Heart Failure Trials | Department of Mathematics & Statistics University of Maryland Baltimore County Baltimore, MD | DoHwan Park, Ph.D. | Further Details |
| 5855 | GSK | A clinical practice for detecting the phases of Herpes Zoster. | * Athens University of Economics and Business, Department of Statistics (www.stat-athens.aueb.gr ) * Frontier Science Foundation Hellas (www.frontier-science.gr ) | Dimitris Karlis | Further Details |
| 5862 | GSK | Impact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus Erythematosus | 1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece | Katerina Chatzidionysiou | Further Details |
| 5865 | GSK | Hospitalized influenza clinical studies: benchmarking and refinement of clinical endpoints | Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services (HHS) | Kimberly Armstrong | Further Details |
| 5880 | Roche | Assessing immune system correlates to individual tumour size dynamics | University of Manchester, Manchester, UK | Dr Hitesh Mistry | Further Details |
| 5881 | Novartis | Relationship between outcomes and systolic blood pressure reduction during the first 24 h in acute heart failure syndrome: an exploratory analysis of the Relax-AHF-studies | The University of Copenhagen, and the Department of Cardiology, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark | Olav Wendelboe Nielsen | Further Details |
| 5886 | GSK | Efficacy of belimumab in patients with active systemic lupus erythematosus and concomitant antiphospholipid syndrome | Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy. | Pier Luigi Meroni | Further Details |
| 5895 | ViiV | Pharmacogenetics of Interaction between Efavirenz and Dolutegravir | Vanderbilt University Medical Center Nashville, Tennessee | David W. Haas, MD | Further Details |
| 5904 | Lilly, Roche | Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer | Iowa State University | Benjamin K Schneider | Further Details |
| 5906 | UCB | Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs | University of Liverpool | Laura Bonnett | Further Details |
| 5915 | GSK | SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials | Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical Immunology | Savino Sciascia | Further Details |
| 5936 | Takeda, UCB | The impact of biological interventions on health-related quality of life in adults with Crohn's disease | UHC rijeka, krešimirova 42, 51000 Rijeka, Croatia | Mirjana Stanic Benic | Further Details |
| 5937 | Roche | Predictors of exposure, therapeutic and adverse effects of tocilizumab used in the treatment of rheumatoid arthritis. | University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5951 | Lilly | Alternative Data Presentation For Treatment Outcomes in Psoriasis | University of Alberta, Faculty of Medicine & Dentistry, Division of Dermatology, Canada | Robert Gniadeki | Further Details |
| 5979 | Lilly | Predictors of exposure, therapeutic and adverse effects of baricitinib used in the treatment of rheumatoid arthritis. | Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5981 | Roche | Multi-state models for the analysis of survival data in radiation therapy. | Department of Radiotherapy, Paoli Calmettes Institute, Marseille, France. | Pierre Annede | Further Details |
| 5988 | Lilly, Novartis, Roche | Pattern Extraction and Patient-Level Prediction of Adverse Events Using Meta-Analysis and Matrix Decomposition | Tokyo University of Science | Kentaro Matsuura | Further Details |
| 5995 | Novartis | An investigation of clinical outcome measures in PPMS to inform the design of investigator initiated clinical trials. | University of Calgary, Calgary, Alberta, Canada | Marcus Koch MD PhD | Further Details |
| 6001 | Lilly | Can I use machine learning to build a prediction model of individual patient outcome in first episode psychosis? | Institute of Mental Health & Wellbeing, University of Glasgow Honorary Specialty Registrar General Adult Psychiatry, NHS Greater Glasgow & Clyde | Dr Samuel Leighton | Further Details |
| 6009 | GSK | Examining Immune Setpoints in Children and Adults Who Received Multivalent Hepatitis B Vaccines | J. Craig Venter Institute (JCVI) | Yun Zhang | Further Details |
| 6042 | Eisai, GSK, Sanofi | An investigation into unblinded sample size re-estimation methodology in clinical trials | The University of Sheffield | Julia Edwards | Further Details |
| 6044 | GSK, Sanofi | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis. | Department of Microbiology, Infectious diseases & Immunology and CHU Sainte-Justine Research Center, Université de Montréal, Montréal, QC, Canada | Caroline Quach | Further Details |
| 6062 | Sanofi | Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysis | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Shirley Yu | Further Details |
| 6066 | Novartis | Evaluating the role of Clinical Study Reports, as unpublished sources of evidence for the use of sacubitril/valsartan in adults and its impact on evidence synthesis. | Department of General Practice and HRB Centre for Primary Care Research | Dr David Byrne | Further Details |
| 6078 | Novartis, Roche | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 6080 | Roche | Exploratory Analysis of CRANE Influenza Study to Assess Impact of MHAA4549A among Subgroups Classified by Influenza Severity | Veristat | Robin Bliss | Further Details |
| 7080 | Roche, Sanofi | The clinical outcome based on the treatment course factors in CLASSIC trial. | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan | Hisaka Akihiro | Further Details |
| 7082 | Roche | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer. | Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon. | Youssef Zeidan | Further Details |
| 8102 | GSK | Open Label Extension Analysis - Exploring Self-Controlled Case Series Methodology | London School of Hygiene and Tropical Medicine | Ian Douglas | Further Details |
| 9115 | GSK | inhaled STerOids for the Prevention of Lung Cancer. (STOP Lung Cancer) | Clínica Universidad de Navarra | Luis Seijo | Further Details |
| 9131 | GSK | Validation of the diabetes microsimulation model in the HARMONY trial | University of Florida College of Pharmacy | Hui Shao | Further Details |
| 9134 | ViiV | Population pharmacokinetic analysis of interaction between dolutegravir and rifampin | Department of Medicine University of Cape Town Health Sciences Faculty | Gary Maartens | Further Details |
| 9136 | Novartis | Association Between Blood Pressure and Cardiovascular Outcomes in Liver Transplant Recipients. | Northwestern University Feinberg School of Medicine | Lisa B VanWagner MD MSc FAST FAHA | Further Details |
| 9140 | Eisai | INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF DONEPEZIL FOR ALZHEIMER'S DISEASE | Kyoto University Graduate School of Medicine / School of Public health | Toshi A. Furukawa | Further Details |
| 10141 | GSK | Impact of rotavirus genotype and local rotavirus gastroenteritis incidence on Rotarix vaccine efficacy estimates: a multi-site pooled analysis of individual-level clinical trial data | Department of Epidemiology, Rollins School of Public Health, Emory University | Avnika B. Amin | Further Details |
| 10189 | Roche | Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 10195 | GSK | Relationship Between Baseline Blood Electrolyte Levels and Risk of Asthma Exacerbation | Gossamer Bio | Greg Opitek | Further Details |
| 10204 | Novartis | Validity of Renal Transplant Outcomes in the Australian and New Zealand Dialysis and Transplant Registry: Comparison with Clinical Trials Data | Employer: Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia Research Affiliation: University of Sydney, Sydney, NSW, Australia | Tracey Ying | Further Details |
| 11223 | Novartis, Roche, Sanofi | Individualizing Treatment Decisions for Adult Relapsing-Remitting Multiple Sclerosis Patients Using Statistical Learning Methods | Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland | Prof Dr Ulrike Held | Further Details |
| 11229 | GSK | Exploration of the Hospital Recovery Scale as an endpoint to assess clinical improvement in hospitalized influenza patients | Janssen R&D Belgium | Wilbert van Duijnhoven | Further Details |
| 11230 | Sanofi | A systematic review of prognostic biomarkers in idiopathic pulmonary fibrosis | University of Nottingham | Prof Gisli Jenkins | Further Details |
| 11236 | GSK | Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) validation: post-hoc analysis of the BLISS-52 and BLISS-76 phase III trials. | Professor of Rheumatology and Head of the CHUC Lupus Clinic, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra. Coimbra, Portugal Professor of Rheumatology at Faculty of Health Sciences, University of Beira Interior. Covilhã, Portugal | Luís Inês | Further Details |
| 11254 | GSK | Evaluation of the pharmacokinetics of valacyclovir in subjects 1 month of age or older in order to assist in the design of a safer, more beneficial study of its pharmacokinetics in neonates under 2 weeks of age. | University of Alabama at Birmingham | David Kimberlin, MD | Further Details |
| 11278 | GSK, Sanofi | Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes | Pharmacologie clinique, Université Grenoble Alpes Centre d'Investigation Clinique, Inserm CIC1406 CHU Grenoble Alpes Laboratoire HP2, Inserm UMR 1042 Tel: 06 73 98 36 37 mroustit@chu-grenoble.fr | ROUSTIT MATTHIEU | Further Details |
| 11280 | GSK | Antibody response to primary and booster immunization in infants born to mothers immunized with pertussis-containing vaccines during pregnancy versus unimmunized women: a systematic review and meta-analysis | University of British Columbia, Canada | Dr. Manish Sadarangani | Further Details |
| 11283 | GSK | Association between Vaginal Infection and Cervical Non-HPV16/18 Infection in Women after Bivalent HPV Vaccination | Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11288 | Novartis | Clinical Trial Diversity for Common Dermatologic Diseases: A Systematic Review | University of Pennsylvania | Junko Takeshita | Further Details |
| 11298 | GSK | Development of personalised predictive models for the evolution of atopic dermatitis severity in response to treatment | Department of Bioengineering, Imperial College London | Reiko Tanaka | Further Details |
| 11302 | GSK | Assessment of the prognostic impact of including standard serological markers in the definitions of remission and low lupus disease activity in patients with SLE | University of Crete Medical School; University Hospital of Heraklion, Greece | George Bertsias | Further Details |
| 11340 | GSK | Towards precision medicine in Chronic Obstructive Pulmonary Diseases: predicting individual treatment response and general outcomes in SUMMIT | University Hospitals Leuven Department of Respiratory Diseases Research Laboratory BREATHE, Department CHROMETA, KU Leuven Herestraat 49 3000 Leuven Belgium | Wim Janssens | Further Details |
| 11347 | GSK | Estimation of primary, secondary and composite effects of the RTSS/AS01 vaccine | London School of Hygiene&Tropical Medicine | Paul Milligan | Further Details |
| 11384 | GSK | Human papillomavirus(HPV) vaccine efficacy and immunogenicity in women with existing HPV infections | National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11385 | Novartis | Can changes in blood eosinophils (white blood cells) following treatment with inhaled corticosteroids predict clinical response in chronic obstructive pulmonary disease? A post-hoc analysis of the FLAME trial. | Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK. and North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. | Prof. Jørgen Vestbo DMSc, FRCP, FERS, FMedSci. | Further Details |
| 11402 | GSK | Examination of Placebo Variance | University of Miami Department of Biochemistry and Molecular Biology Miller School of Medicine | Edward Bowen | Further Details |
| 11435 | GSK | Natural history of human papillomavirus and associated lesions in healthy Chinese women | National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11485 | Novartis, Sanofi | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | The University of Texas Southwestern Medical Center | Amber Salter | Further Details |
| 11487 | GSK | A secondary Data-Analysis of Post-Traumatic Stress Disorder (PTSD) and Clinician-Administered PTSD Scale for DSM-5 (CAPS- 5) | Tunnell Government Services, Inc., Subcontractor to General Dynamics Information Technology (GDIT) working in support of US Army Medical Materiel Development Activity, Warfighter Brain Health (WBH) Project Management Office (PMO) | Elyse Katz, Ph.D. | Further Details |
| 11492 | Eisai, Novartis | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies. | UMCG | Iris Sommer | Further Details |
| 11504 | GSK | Translating randomized controlled trial data to an external target population: a secondary analysis of data from the RV1 trial in South Africa and Malawi | University of North Carolina at Chapel Hill, Department of Epidemiology | Denise St. Jean | Further Details |
| 11506 | GSK | Review of the relation of parasite density and symptomatic disease in malaria infections | World Health Organization | Jane Cunningham | Further Details |
| 11520 | Sanofi | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Statistics, Purdue University | Arman Sabbaghi | Further Details |
| 11529 | Sanofi | B cells and disease activity and anti-drug responses prior to and following alemtuzumab infusion for multiple sclerosis | Blizard Institute Barts and the London School of Medicine Queen Mary University of London | David Baker | Further Details |
| 11560 | GSK | Emotional blunting by mechanism of second-generation antidepressants: comparing bupropion and serotonin reuptake inhibitors | University of Saskatchewan, Department of Psychiatry | Dr. Evyn Peters | Further Details |
| 11593 | Sanofi | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Dr Shirley Yu | Further Details |
| 11597 | Astellas, GSK, Novartis | Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms | Psychiatrist at CHU Rennes and Professor at Université de Rennes 1 | Florian Naudet | Further Details |
| 11627 | GSK | Validation of the diabetes Chronic Kidney Disease (CKD) and Heart Failure (HF) model in the HARMONY Outcomes trial | Tulane University School of Public Health and Tropical Medicine | Lizheng Shi | Further Details |
| 11654 | GSK, Sanofi | An individual participant data meta-analysis to evaluate a new category of hypoglycemic drugs (GLP-1RAs) on type 2 diabetes mellitus patient sub-groups | School of public health, Peking University | Feng Sun | Further Details |
| 11673 | GSK | Examination of new systemic lupus erythematosus (SLE) activity index development | Department of Rheumatology, Kobe City Medical Center General Hospital | Shuji Sumitomo | Further Details |
| 11683 | GSK, Novartis | A systematic review of the steroid sparing effect of biologicals in severe asthma | EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Portugal & Faculdade de Medicina da Universidade do Porto, Portugal & Centro Hospitalar São João, Porto, Portugal | André Moreira | Further Details |
| 11697 | GSK | Modelling approaches for antibody decay of malaria vaccines | Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Disease National Institutes of Health | Jennifer Kwan | Further Details |
| 11714 | Novartis | The Difference Between Cystatin C- and Creatinine- Based Assessment of Renal Function in Heart Failure Patients: Insights From PARADIGM-HF and RELAX-AHF | Columbia University Medical Center | Alberto Pinsino | Further Details |
| 11730 | Astellas | Promising subgroup identification method based on biomarkers for precision medicine. | Biostatistics department of Public Health school, Harbin Medical University, China | Kang Li | Further Details |
| 11731 | GSK | Assessing the impact of season and schedule of vaccination on the immunogenicity of childhood vaccines | Max Planck Institute for Infection Biology | Sarah Kramer | Further Details |
| 11772 | ViiV | Determining an optimal pharmacokinetic target for dolutegravir | Pharmacometrics Laboratory, Division of Clinical Pharmacology, The University of Cape Town. | Aida N Kawuma | Further Details |
| 11795 | Novartis | The effects of systemic anti-infective concomitant medications on progression of neurological diseases | experimind | Chaim Singal | Further Details |
| 11798 | Eisai, GSK, Novartis | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | Edinburgh Clinical Trials Unit - The University of Edinburgh | Aryelly Rodriguez | Further Details |
| 11801 | Sanofi | Regulatory decision criteria on the suitability of the glycated hemoglobin level (HbA1c) as a surrogate for cardiac events. | Hochschule Koblenz - RheinAhrCampus Fachbereich Mathematik und Technik | Malwina Mackowiak | Further Details |
| 11808 | GSK | Evaluating the role of stochasticity in the clearance of HPV infections in young adults. | MIVEGEC department, CNRS (Montpellier, France) | Samuel ALIZON | Further Details |
| 11833 | GSK, Novartis | Development, Validation, and Implementation of an Individualized Risk Prediction Tool for Exacerbations in Severe Asthma | National University of Singapore | Wenjia Chen | Further Details |
| 11874 | GSK | Examine the efficacy and safety of Belimumab in treatment of newly diagnosed Systemic Lupus Erythematosus in Chinese population | Peking Uion Medical College Hospital | Xiaomei Leng | Further Details |
| 11879 | GSK | Predicting individual treatment effects with machine learning in IMPACT | University Hospitals Leuven Department of Respiratory Diseases Research Laboratory BREATHE, Department CHROMETA, KU Leuven Herestraat 49 3000 Leuven Belgium | Wim Janssens | Further Details |
| 11915 | GSK | Artificial Intelligence Algorithms for Analysis of Geographic Atrophy | Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. | Amitha Domalpally | Further Details |
| 11927 | GSK | EVALUATION OF THE EFFECTS OF CARDIOVASCULAR DRUGS ON SURVIVAL AND EXACERBATIONS IN PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | University of Cambridge & Cambridge University Hospitals NHS Foundation Trust | Marie Fisk | Further Details |
| 11950 | GSK, Novartis | Making real world predictions for clinical outcomes in Relapsing-Remitting Multiple Sclerosis | Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland | Georgia Salanti | Further Details |
| 11973 | Novartis | Evaluation of acute changes in kidney function with serelaxin in acute heart failure | Tufts Medical Center, Tufts University School of Medicine | Wendy McCallum, MD, MS | Further Details |
| 11995 | GSK | Study to Evaluate Plasmodium vivax malaria pharmacometric Responses in blood and liver staGes to Eight AminoquinoliNe Treatments (SARGEANT) | Mahidol Oxford Tropical Medicine Research Unit | Nicholas J White | Further Details |
| 11996 | GSK | A Hidden Markov Modelling Approach for Measuring Migraine Treatment Success | University of Illinois at Urbana-Champaign | Eric A. Wayman | Further Details |
| 11998 | GSK | Prediction of efficacy and tolerability of antidepressants and mood stabilizers | Department of Psychiatry and Psychotherapy, Charité Campus Mitte, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany | Lasse Brandt | Further Details |
| 12004 | Novartis | Surgical Margin Distance in Head and Neck Squamous Cell Carcinoma | Karmanos Cancer Institute, Wayne State Univeristy | John David Cramer, MD, FACS | Further Details |
| 12016 | GSK | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Royal College of Surgeons in Ireland | Frank Doyle | Further Details |
| 12023 | GSK | A Machine Learning Approach Identifies Modulators of Albiglutide on Preventing Cardiovascular and Renal Outcomes in People with Type 2 Diabetes: A Revisit to the HARMONY trial | University of Florida College of Pharmacy | Hui Shao | Further Details |
| 12036 | Novartis | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours_Novartis_032022 | Flinders University | Dr Ashley Hopkins | Further Details |
| 12051 | Novartis | Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials | University Paris Est Creteil (UPEC) | Emilie Sbidian | Further Details |
| 12088 | Novartis | Using modern causal inference methods to enhance the generalisability of randomised controlled trial evidence by leveraging observational data: the case of Deferasirox® for managing iron overload in transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS) patients | Centre for Health Economics, University of York, UK | Andrea Manca | Further Details |
| 12095 | GSK | Interpersonal sensitivity and response to selective serotonin reuptake inhibitors | Department of Psychiatry, University of Saskatchewan | Dr. Evyn Peters, MD, FRCPC, MSc | Further Details |
| 12126 | Novartis | SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Department of Rheumatology, Zuyderland Medical Center, Heerlen, the Netherlands | Sofia Ramiro | Further Details |
| 12132 | GSK, Novartis | The Incidence of Screen Failures Among African American Patients in Clinical Trials Due to Low White Blood Cell Counts | Stanford University | Matthew Baker | Further Details |
| 12135 | GSK | Examining alternative core symptom inclusion criteria in randomized placebo-controlled trials for acute major depression | Department of Psychiatry, University of Saskatchewan | Dr. Evyn Peters, MD, FRCPC, MSc | Further Details |
| 12149 | GSK | Developing a quantitative base for more effective and individualized ropinirole dosing regimen | Faculty of Pharmacy, Jagiellonian University Medical College in Poland | Sebastian Polak | Further Details |
| 12167 | Novartis | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in COPD: randomised COntrolled trials individual participant Data re-Evaluation. | 1. North West Lung Centre, Manchester University NHS Foundation Trust. 2. Division of Immunology, Immunity to Infection & Respiratory Medicine, The University of Manchester. | Alexander G Mathioudakis | Further Details |
| 12178 | GSK | Population Pharmacokinetic Study involving different formulations of Salbutamol | OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal | Nuno Filipe de Sousa Vale | Further Details |
| 12205 | Novartis | Pretreatment Lymphocyte Count and Response to Concurrent Chemoradiation in Head and Neck Cancer | Karmanos Cancer Institute, Wayne State University | John Cramer, MD, FACS | Further Details |
| 12227 | Novartis | What is the most clinically significant endpoint for CAR-T therapeutic approach to achieve effective results for lymphoma patients: should we consider CAR-T cell therapy as a drug or as a therapeutic pathway? | ALMA MATER STUDIORUM - Università di Bologna, Department of Medical and Surgical Sciences | Lisa Argnani | Further Details |
| 12243 | Novartis | Validation of a Personalised Axial Spondyoarthritis Metrology Index Using Data from Clinical Trials. | Care and Public Health Research Institute CAPHRI, Maastricht, the Netherlands | Dafne Capelusnik | Further Details |
| 12282 | Novartis | Selection of comparable subjects from different treatment groups when randomization is not feasible | Business Transformation Solutions Global Business Solutions Novartis Healthcare Pvt. Ltd. Salarpuria-Sattva Knowledge City Raidurg, Rangareddy District Madhapur / Hyderabad, Rangareddy 500008 | SHYAM BIHARI TIWARI | Further Details |
| 12305 | GSK, Novartis | Effectiveness of different treatments in Chronic obstructive pulmonary disease patients: an individual patient data pooled analysis of RCTs | National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University | Zihui Wang | Further Details |
| 12306 | Novartis | Mathematical modeling of patient-specific multiphasic dynamics of CAR-T cells, their interaction with healthy B cells, and the development of resistance. | National Laboratory for Scientific Computing in Brazil (LNCC) | Regina Célia Cerqueira de Almeida | Further Details |
| 12318 | GSK | Persistent and isolated serum low C3 and lupus nephritis | Azienda Sanitaria Liguria 5- La Spezia (Italy) | Lucio Manenti | Further Details |
| 12369 | Novartis | Machine learning-based identification of the target population for angiotensin-neprilysin inhibition given its heterogeneous treatment effect: a post-hoc analysis of the PARADIGM-HF and PARAGON-HF trials | Columbia University Irving Medical Center | Itsuki Osawa | Further Details |
| 12377 | Novartis | Improving heart failure with reduced ejection fraction (HFpEF) treatment using a mathematical model of physiology | University of Mississippi Medical Center | John S. Clemmer | Further Details |
| 12388 | GSK | High-risk human papillomavirus genotyping concordance between paired cervical exfoliated cells and biopsies | National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 12390 | Novartis | Evaluating the impact of angiotensin receptor blocker use on the response to Icenticaftor. | University of Kansas Medical Center Department of Internal Medicine | Matthias Salathe | Further Details |
| 12410 | Novartis | Project 1: Comprehend common behavior patterns in different clinical trials, considering perspectives such as subject safety, study endpoints, and others. Project 2: Develop an algorithm(s) for the identification of "Duplicated Subjects". | Cyntegrity Germany GmbH | Anastasia Shapovalova | Further Details |
| 12414 | GSK | Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of three Phase 3 randomised controlled trials of belimumab. | Monash University School of Clinical Sciences | Kathryn Connelly | Further Details |
| 12427 | GSK | A comparative study of anti-hypertensive drugs prediction models for the elderly based on machine learning algorithms | China Pharmaceutical University | Guo Yu | Further Details |
| 12428 | Novartis | Association of Obesity and Incidence of Lung Cancer with Interleukin-1β Antagonism | Roswell Park Comprehensive Cancer center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo Buffalo, New York, USA. 14201 | SAI YENDAMURI | Further Details |
| 12435 | Novartis | Effectiveness and safety of janus kinase inhibitors in hospitalized patients with COVID-19: Systematic review and individual patient data meta-analysis of randomized trials | 1) CLEAR Methods Center, Division Clinical Epidemiology, Department Clinical Research, University Hospital Basel (Prof. M. Briel, MD PhD) 2) Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Oslo, Norway (Dr. Inge Olsen, PhD) 3) Bristol Medical School, Medical Statistics, University of Bristol, UK (Prof. Jonathan Sterne, PhD). This project is supported and reviewed by Prof. M. Briel, he is my main mentor. | Alain Amstutz MD PhD | Further Details |
| 12456 | Novartis | Systematic review and network meta-analysis of the efficacy and safety of systemic treatments in patients affected by chronic urticaria. | 1 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. 2 Evidence in Allergy Group, McMaster University, Hamilton, ON, Canada. 3 Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 4 The Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada. | Derek Chu | Further Details |
| 12525 | Novartis | Evaluating the Impact of Comorbidities on the Efficacy of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure Patients with Preserved Ejection Fraction | Department of Cardiology, Yongin Severance Hospital, Yonsei University College of Medicine, South Korea | SungA Bae | Further Details |